Company news

Verastem, Inc. news in 2021

Verastem, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer

November 21, 2021

Verastem Oncology to Present at the Jefferies London Healthcare Conference

November 10, 2021

Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

November 3, 2021

Verastem Oncology Appoints Michelle Robertson to Board of Directors

October 25, 2021

Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer

September 21, 2021

Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer

September 19, 2021

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

September 18, 2021

Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

August 1, 2021

Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021

July 26, 2021

Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt

July 18, 2021

Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors

June 23, 2021

Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference

May 24, 2021

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

May 23, 2021

Verastem Oncology Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

May 10, 2021

Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results, Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022

March 17, 2021

Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference

March 1, 2021

Frank Neumann, M.D., Ph.D., to Depart Verastem Oncology

January 19, 2021

Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer

January 5, 2021

Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference

January 4, 2021

Decks in 2021